> 0 1 0 1 O
6 2 3 2 3 B-lower_bound
months 4 10 4 10 I-lower_bound
must 11 15 11 15 O
have 16 20 16 20 O
elapsed 21 28 21 28 O
if 29 31 29 31 O
prior 32 37 32 37 O
craniospinal 38 50 38 50 B-treatment
XRT 51 54 51 54 I-treatment

Burkitt 0 7 55 62 B-cancer
Lymphoma 8 16 63 71 I-cancer

CD20 0 4 72 76 B-cancer
+ 4 5 76 77 I-cancer
B 6 7 78 79 I-cancer
- 7 8 79 80 I-cancer
lymphoblastic 8 21 80 93 I-cancer
lymphoma 22 30 94 102 I-cancer

Date 0 4 103 107 O
of 5 7 108 110 O
receiving 8 17 111 120 O
prior 18 23 121 126 O
XRT 24 27 127 130 B-clinical_variable
must 28 32 131 135 O
be 33 35 136 138 O
> 36 37 139 140 O
2 38 39 141 142 B-lower_bound
weeks 40 45 143 148 I-lower_bound
for 46 49 149 152 O
local 50 55 153 158 O
palliative 56 66 159 169 O
XRT 67 70 170 173 O
( 71 72 174 175 O
small 72 77 175 180 O
port 78 82 181 185 O

Diffuse 0 7 186 193 B-cancer
Large 8 13 194 199 I-cancer
B 14 15 200 201 I-cancer
- 15 16 201 202 I-cancer
Cell 16 20 202 206 I-cancer
Lymphoma 21 29 207 215 I-cancer

Follicular 0 10 216 226 B-cancer
lymphoma 11 19 227 235 I-cancer
, 19 20 235 236 O
Grade 21 26 237 242 O
III 27 30 243 246 O

High 0 4 247 251 O
Grade 5 10 252 257 O
B 11 12 258 259 B-cancer
- 12 13 259 260 I-cancer
cell 13 17 260 264 I-cancer
Lymphoma 18 26 265 273 I-cancer
: 26 27 273 274 O
Not 28 31 275 278 O
Otherwise 32 41 279 288 O
Specified 42 51 289 298 O
( 52 53 299 300 O
NOS 53 56 300 303 O
) 56 57 303 304 O

History 0 7 305 312 O
of 8 10 313 315 O
grade 11 16 316 321 O
4 17 18 322 323 O
anaphylactic 19 31 324 336 O
reactions 32 41 337 346 O
to 42 44 347 349 O
humanized 45 54 350 359 B-allergy_name
or 55 57 360 362 O
murine 58 64 363 369 B-allergy_name
monoclonal 65 75 370 380 I-allergy_name
antibodies 76 86 381 391 I-allergy_name

Karnofsky 0 9 392 401 B-clinical_variable
≥ 10 11 402 403 O
60 12 14 404 406 B-lower_bound
% 14 15 406 407 I-lower_bound
for 16 19 408 411 O
patients 20 28 412 420 O
> 29 30 421 422 O
16 31 33 423 425 B-lower_bound
years 34 39 426 431 I-lower_bound
of 40 42 432 434 O
age 43 46 435 438 B-age

Known 0 5 439 444 O
congenital 6 16 445 455 B-chronic_disease
or 17 19 456 458 I-chronic_disease
acquired 20 28 459 467 I-chronic_disease
immune 29 35 468 474 I-chronic_disease
deficiency 36 46 475 485 I-chronic_disease

Lansky 0 6 486 492 B-clinical_variable
≥ 7 8 493 494 O
60 9 11 495 497 B-lower_bound
for 12 15 498 501 O
patients 16 24 502 510 O
≤ 25 26 511 512 O
16 27 29 513 515 B-upper_bound
years 30 35 516 521 I-upper_bound
of 36 38 522 524 O
age 39 42 525 528 B-age

Must 0 4 529 533 O
not 5 8 534 537 O
have 9 13 538 542 O
received 14 22 543 551 O
within 23 29 552 558 O
2 30 31 559 560 B-upper_bound
weeks 32 37 561 566 I-upper_bound
of 38 40 567 569 O
entry 41 46 570 575 O
onto 47 51 576 580 O
this 52 56 581 585 O
study 57 62 586 591 O

Patients 0 8 592 600 O
in 9 11 601 603 O
first 12 17 604 609 O
relapse 18 25 610 617 O
or 26 28 618 620 O
primary 29 36 621 628 O
induction 37 46 629 638 O
failure 47 54 639 646 O
CD20 55 59 647 651 B-cancer
positive 60 68 652 660 I-cancer
B 69 70 661 662 I-cancer
- 70 71 662 663 I-cancer
cell 71 75 663 667 I-cancer
leukemia 76 84 668 676 I-cancer
/ 84 85 676 677 I-cancer
lymphoma 85 93 677 685 I-cancer

Patients 0 8 686 694 O
may 9 12 695 698 O
have 13 17 699 703 O
received 18 26 704 712 O
prior 27 32 713 718 B-treatment
steroid 33 40 719 726 I-treatment
treatment 41 50 727 736 I-treatment
, 50 51 736 737 O
but 52 55 738 741 O
not 56 59 742 745 O
started 60 67 746 753 O
greater 68 75 754 761 O
than 76 80 762 766 O
7 81 82 767 768 B-lower_bound
days 83 87 769 773 I-lower_bound
prior 88 93 774 779 I-lower_bound
to 94 96 780 782 I-treatment
initiation 97 107 783 793 I-treatment
of 108 110 794 796 I-treatment
protocol 111 119 797 805 I-treatment
therapy 120 127 806 813 I-treatment

Patients 0 8 814 822 O
may 9 12 823 826 O
not 13 16 827 830 O
have 17 21 831 835 O
received 22 30 836 844 O
prior 31 36 845 850 B-treatment
therapy 37 44 851 858 I-treatment
with 45 49 859 863 I-treatment
obinutuzumab 50 62 864 876 I-treatment
( 63 64 877 878 I-treatment
GA101 64 69 878 883 I-treatment
) 69 70 883 884 I-treatment

Patients 0 8 885 893 O
with 9 13 894 898 O
newly 14 19 899 904 O
diagnosed 20 29 905 914 O
, 29 30 914 915 O
previously 31 41 916 926 O
untreated 42 51 927 936 O
B 52 53 937 938 B-cancer
- 53 54 938 939 I-cancer
NHL 54 57 939 942 I-cancer

Primary 0 7 943 950 B-cancer
mediastinal 8 19 951 962 I-cancer
B 20 21 963 964 I-cancer
- 21 22 964 965 I-cancer
cell 22 26 965 969 I-cancer
lymphoma 27 35 970 978 I-cancer
( 36 37 979 980 I-cancer
PMBL 37 41 980 984 I-cancer
) 41 42 984 985 I-cancer

Prior 0 5 986 991 B-treatment
allogeneic 6 16 992 1002 I-treatment
stem 17 21 1003 1007 I-treatment
cell 22 26 1008 1012 I-treatment
transplant 27 37 1013 1023 I-treatment
within 38 44 1024 1030 O
60 45 47 1031 1033 B-upper_bound
days 48 52 1034 1038 I-upper_bound
or 53 55 1039 1041 O
active 56 62 1042 1048 O
acute 63 68 1049 1054 B-chronic_disease
Graft 69 74 1055 1060 I-chronic_disease
- 74 75 1060 1061 I-chronic_disease
vs 75 77 1061 1063 I-chronic_disease
- 77 78 1063 1064 I-chronic_disease
Host 78 82 1064 1068 I-chronic_disease
- 82 83 1068 1069 I-chronic_disease
Disease 83 90 1069 1076 I-chronic_disease
( 91 92 1077 1078 I-chronic_disease
GVHD 92 96 1078 1082 I-chronic_disease
) 96 97 1082 1083 I-chronic_disease
grade 98 103 1084 1089 B-lower_bound
3 104 105 1090 1091 I-lower_bound
or 106 108 1092 1094 O
higher 109 115 1095 1101 O

Prior 0 5 1102 1107 B-treatment
solid 6 11 1108 1113 I-treatment
organ 12 17 1114 1119 I-treatment
transplantation 18 33 1120 1135 I-treatment

Radiation 0 9 1136 1145 B-treatment
Therapy 10 17 1146 1153 I-treatment
( 18 19 1154 1155 I-treatment
XRT 19 22 1155 1158 I-treatment
) 22 23 1158 1159 I-treatment

Steroids 0 8 1160 1168 B-treatment

Uncontrolled 0 12 1169 1181 B-chronic_disease
hepatitis 13 22 1182 1191 I-chronic_disease
B 23 24 1192 1193 I-chronic_disease
and/or 25 31 1194 1200 I-chronic_disease
C 32 33 1201 1202 I-chronic_disease
infection 34 43 1203 1212 I-chronic_disease

